Bio-treatments on the rise for osteoarthritis, says GlobalData

 

The osteoarthritis device market is experiencing healthy growth, with a 6% Compound Annual Growth Rate expected for years to come, and injectable treatments moving towards biological approaches, according to GlobalData, a leading data and analytics company.

Osteoarthritis is one of the developed world’s most common diseases, with over 80% of the senior population suffering from knee or hip osteoarthritis. With a rapidly aging global population and over half of osteoarthritis patients suffering from symptomatic pain, there are a wide variety of surgical treatments available.

Sarah Janer, Healthcare Analyst at GlobalData, comments: “Despite the increasing lifespans of orthopedic implants and the safety of minimally invasive procedures, many patients remain reluctant to undergo operations and are opting to explore orthobiologic options such as hyaluronic or stem cell injections instead.”

Industry players are developing new injectable options as demand grows for viscosupplementation, a technology that uses injections to cushion the joint with worn cartilage.

Most injectables use hyaluronic acid but many players are moving towards other biological approaches, such as harvesting and injecting patients’ own stem cells. Regenexx has offered stem cell injections for several years, and its co-founder has boldly predicted that the company’s technology will eventually replace orthopedic surgery. Mimedx has continued to aggressively push its studies of Purion Processed AmnioFix, an injectable that could be used to protect the knee’s collagen matrix and expand treatment options for osteoarthritis of the knee using amniotic tissues.

Janer adds: “Injectable treatments are popular as, unlike implantation surgery, patients are not forced to take time off of work to recover. Orthobiologic injectables have minimal recovery times and some require only one injection. Hyaluronic acid supplements add cushioning and help manage pain, but stem cell or amniotic tissue injectables can help patient’s regenerate new cartilage.

“As patients continue to opt towards regenerative non-invasive procedures, companies like Mimedx and Regenexx could very well be at the forefront of the future of standard orthopedic treatments.”

Source: GlobalData

Aventics produces pneumatic components for all tasks in medical engineering

Aventics products can be found in all areas of medical engineering: They prepare and distribute air and oxygen as well as medical gases in hospitals, and supply patients with oxygen through mobile oxygen concentrators. Pneumatic components make shock wave therapy and anesthesia possible. They are used in mobile emergency equipment and monitoring devices, such as stationary blood pressure monitors. And Aventics valves, cylinders, and sensors are also key components in industrial automation for manufacturers of medical technologies.

Aventics customers benefit from the company’s many years of experience in safety-relevant industries. “Functional safety and reliability are not only considered theoretical product advantages – we know that they are essential properties in many life sciences applications,” emphasizes Paul Gant, Director Global Life Sciences at Aventics. This applies both to automatic production systems and medical equipment. Thanks to worldwide support, developers can always reach out to a competent contact, providing support in selecting the right components or designing customer-specific components and incorporating the expertise of a global manufacturer. “By the way, it’s not just our products that are reliable, but the entire chain – from ordering to delivery, to after-sales services,” continues Gant.

Small, lightweight, and smart
Aventics is promoting two major trends in particular: Compact, lightweight pneumatic components mobilize many medical devices that were once only available for stationary applications. The company is also driving networking forward: Aventics components enable functional monitoring and predictive maintenance, as well as the control of complex functionalities.

Aventics places a special focus on developer support. A wide range of web-based tools make choosing components and designing equipments and systems easy. The online portal contains configurators, CAD tools, calculation programs, and a shop that allow users to order fully configured components. An internal team of experts is also available for complex engineering tasks for customer-specific solutions, including building prototypes.

Source: Aventics

Medica Health IT forum highlights the opportunities and prospects for doctors and patients

“Izzy is your friend. She understands you and helps you to be prepared by keeping track of your menstrual cycle”: this is what you’ll find if you type “Izzyperiod” into the Facebook search box. It has already been shared over a thousand times and gleaned over 750 comments before the end of August. If Izzy was a person, this wouldn’t be out of the ordinary: but Izzy is, in fact, a chatbot. Text-based systems like these, which anyone can have a “natural” conversation with online, are on the rise worldwide. They are tipped to have massive development potential in the healthcare system. The MEDICA HEALTH IT FORUM at the world’s leading medical trade fair, MEDICA 2017, taking place from 13 – 16 November in Düsseldorf with over 5,000 exhibitors, offers an exciting overview and perspective on the topics and trends that are set to shape the digitalisation of medicine. Artificial intelligence (AI), precision medicine, medical support via the internet which uses big data and participatory health as well as chatbots: this year offers a huge range of options at this long-established forum.

“We’re developing a female chatbot, based on Facebook Messenger. She’s called Izzy”, began Dr Hajnalka Hejja, a doctor and the founder and CEO of Smart Health UG aka MediLad. Hejja is one of the speakers at the MEDICA HEALTH IT FORUM. Her session is called “In case of discomfort, ask your chatbot: Intelligent robots and apps enter the healthcare ecosystem” (Monday, 13 November, from 1:20 pm). Izzy is a friendly voice for young women that want to learn more about reproductive health. She’s not for preventing pregnancies. Smart Health UG aka MediLad leaves that task to other service providers. Izzy’s primary application is predicting menstruation and ovulation. The difference between Izzy and apps is that Izzy does not require installation of an app or software and interacting with Izzy is thus completely different. This is because interaction takes place in the form of a conversation, between the user and the female chatbot (via Facebook Messenger). Only a little data needs to entered to determine the menstrual cycle with sufficient accuracy.

So far, young women from the USA and Britain have been the main users of this service, according to Dr Hajnalka Hejja. “Although Izzy is only currently available in English, there are also a few German users”, said Hejja. The chatbot service is targeted at all young women who grew up in social environments where discussing aspects of pregnancy was tough or impossible. Izzy is free to use, but services such as these also require that financing be secured.

Germany would be a good location to establish high-quality applications in the healthcare system, said Hejja. There are numerous private insurers and private service providers who would be ready to pay for these innovative forms of information and communication. “Our plan is to develop specific services with companies whose target group is female. We’re currently looking for partners in this area”, said Hejja. Izzy wants to continue its development, becoming a market place for feminine healthcare products. Communication via Facebook Messenger would just be the first distribution path, from the viewpoint of Smart Health UG aka MediLad. Other messenger services such as Telegram or Kik would follow. Hejja admits that using a chatbot in the healthcare system is quite unusual at this current point in time. “However, this will change because our society is changing. This also applies to Germany”.

Research knowledge is brought to the patient quicker
Services like these are a component of the digitalisation craze in medicine, and the empowerment of patients that goes with it, as provided by implementation of IT in precision medicine, for example. This area also paves the way to the future. The Federal Minister for Research, Professor Johanna Wanka, recently stated that the government has provided a total of 700 million Euros for research in precision medicine in this legislative term. However, she also stated that there are still hurdles to be overcome in getting research knowledge to patients quickly. This is the main focus of Professor Erwin Böttinger’s research. The former Leader of the Berlin Institute of Health (BHI) has transferred to the Hasso-Plattner Institute (HPI) and is slated as a keynote speaker at the panel discussion “The future is digital: How data and analytics will transform the healthcare market (in the next 5 years)” at the MEDICA HEALTH IT FORUM on Monday 13 November. He doesn’t rule out the notion that the BHI and the HPI might cooperate on some projects in the future. At BHI, they’re focusing on advancing the development of clinical decision-making aids for implementation in real time at the point of care. This even includes activity in education, higher education and further training.

Precision medicine from the “Data Cloud”
Böttinger explained his path: “Now, at HPI, I can drive precision medicine forward in a very focused way, by developing new digital solutions. That’s why I took on the position of Head of the Digital Health Center at the HPI”. The aim of the work there is to develop a “health cloud”, a comprehensive, patient-controlled health data platform that can be accessed anywhere and empowers patients and supports healthcare facilities and staff in handling chronic illnesses and providing healthcare.

Patients and healthcare staff alike can thus open up completely new perspectives for themselves. The patient makes their data available. Data from clinical studies is readily available. An algorithm brings both data sets together and uses them to calculate whether the patient is eligible to take part in a study, and if they are then which one. Patients and doctors can benefit from research and science almost immediately. The informed patient and their doctor thus make a decision together on which therapy path should be taken, where applicable. Research is brought to patients very quickly, and the roll-out of this technology ensures that it is implemented as widely as possible: “We wanted this to be applied with as wide a scope as possible”, Böttinger said, explaining his ambitious aim. It doesn’t matter whether the healthcare entity is a regional group of care facilities, university clinics or private facilities. The main factor in making it a success is having regional partners from the various areas that want to develop solutions together. The organisation of the German healthcare system poses challenges to all stakeholders here. This is because transferring data between sectors is difficult in this country, and this has not changed – and it also makes it difficult to trace a patient’s progress and history, or even to present it properly.

Encouraging experiences in the USA
However, the American experience in this sector is encouraging. Böttinger was able to put medical research into practice at the renowned Mount Sinai Health System in New York: “We’ve got a trans-national program for implementing pharmacogenomics there”. Böttinger set up a team to deal with Clopidogrel, for example. This anticoagulant (thrombocyte aggregation inhibitor) is frequently used after coronary angioplasties, among other illnesses. In this group of patients, around a quarter are resistant to Clopidogrel. This means that these patients cannot benefit from this treatment and thus their risk of an infarction, a stroke and other illnesses remains high. This resistance is determined by genes and can be detected using genetic data.

The patient can only benefit from this technology if their genomic data are available and are used, however. The software for this was created at Mount Sinai, and it will initially mainly be used to support doctors in finding therapies. If the doctor prescribes Clopidogrel and enters this into the patient’s electronic file, then the program checks whether this patient has had genetic tests carried out on them which are available in real time. If this analysis shows that the patient is Clopidogrel-resistant, then this information is displayed on the Doctor’s screen. The software then suggests an alternative medication.

In reality, can this approach be used to a far wider extent: can it really be transferred over to the many, distinct branches of the German healthcare system? In Böttinger’s opinion, the solutions that will significantly improve healthcare will be comprehensive cloud-based solutions that can cross all sectors to integrate data, with this data even being managed by the patients themselves. In comparison to the official infrastructure of telematics, this would save costs, improve the quality of care, enable care to be user-oriented and ultimately offer the patient more comfort and convenience. Böttinger added: “The health card could be a step in this direction”.

Data as a business model? Not for doctors and clinics
Currently, electronic health cards aren’t the driving force behind developing cloud-based solutions. It’s actually powerful groups such as Amazon and Google that are driving this forward in the healthcare system. Undoubtedly, their interest in this is commercial. This could pave the way for other service providers: “I think that confidence and trust are particularly important in medical research” said Böttinger. He believes that German healthcare facilities should use data, provided that patients have actively consented to this. “However, using data as a business model hasn’t ever been considered as an option for doctors and hospitals”, underlined Böttinger. Instead, solutions which serve the interests of the public are far more important, e.g. the HPI wants to develop a comprehensive health data platform. The digitalisation of medicine should automatise many services, such as documentation and issuing prescriptions, and free up medical staff for more important tasks. “Lightening the burden of our colleagues is one objective in our work”. Böttinger makes this an integral part of his projects. The drive to empower the patient does not contravene this objective, because ultimately everyone can benefit from excellent therapy and care for ill people.

Combining big data and AI saves lives
The empowerment of the patient is also one of xbirds’ objectives. The victor of the eHealth Venture Summit at last year’s MEDICA HEALTH IT FORUM has set itself a lofty goal: “By 2020, we want to have saved a million lives”. This objective should be achieved by using big data and artificial intelligence (AI). The app that they have developed collects all available data from smartphones or other end devices such as wearables, fitness trackers and smart watches. These data are combed through for situations which occur concomitantly with undesirable events, which have not actually occurred but which are statistically significant. In a nutshell: The reading and collection of vital function and movement data can be compared to parameters that are typical for the occurrence of certain incidents or symptoms and supply advice on whether the user of the app is at risk of a relapse or if their condition may get worse.

More concretely, this is already being examined in clinical trials to check that this concept is reliable for diabetics. Continuous monitoring of various data and coordinates creates an overview of the patient’s normal daily routine, and automatically finds all of the factors that have a higher probability of occurring in conjunction with hypoglycaemic events (i.e. long periods of sitting, falls). The user would then receive a notification for this, with a prompt to eat something or a warning to see a doctor immediately, for example. This, on the one hand, provides early detection of illness and on the other provides patients with a better understanding of the concomitant events that occur with their individual illness and enables them to improve their therapy and day-to-day dealings with their disease.

As the specialist audience at the MEDICA HEALTH IT FORUM has become more and more international over the passing years, as has MEDICA itself, most program events at the forum, along with their presentations, speeches and discussions, are held in English. One exception to this rule is the main focus event, “Telemedicine”, on Wednesday 15 November (11 am to 5 pm). Under the management of the Center for Telematics and Telemedicine (ZTG) and the German Society for Telemedicine (DG Telemed), this focuses on the European Union’s strategy for digital medicine and the digital agenda of the current Estonian presidency of the Council of the European Union, to give two examples. Estonia is also particularly keen on innovation, in terms of its digital infrastructure and the organisation of its healthcare system.

All information about the MEDICA HEALTH IT FORUM’s programme and topics are available online at: http://www.medica-tradefair.com/mhif2

Author reference: Dr Lutz Retzlaff, freelance medical journalist (Neuss)

Source: Medica

State of the art Dubai-based medical centre now open in Jumeirah

September marked the official inauguration of King’s College Hospital London’s (KCH) new Medical Centre in Jumeirah. The new facility of the London-based, world-renowned teaching hospital, is set to deliver world-leading expertise and enhanced patient journeys across more than ten specialties including paediatrics, fetal medicine, diabetes, and endocrinology.

The inauguration was attended by high-level executives and VIP dignitaries including, H.E. Humaid Al Qutami, Chairman of the Board and Director-General of the Dubai Health Authority; and representatives from KCH UAE’s three joint venture investors; H.E. Ahmed H. Al Tayer, Chairman of KCH UAE; Khalid Bin Kalban, Managing Director and CEO of Dubai Investments PJSC; and Ahsan Ali, Head of Business Operations and Healthcare, Ashmore Group Plc.

“There is nothing more important to us than our patients’ needs and supporting the UAE’s impressive healthcare vision of providing access to quality healthcare through a best in class primary, secondary and tertiary care network of facilities. That is why we’ve brought over 175 years of King’s experience and our unique evidence based healthcare approach to the UAE. Working in close collaboration with an extensive care network, our dedicated team of healthcare professionals will provide the very best of British end-to-end healthcare, across a range of disciplines. Helping to not only service the needs of the community but also further our ambitions to be the local healthcare provider of choice,” Neil Buckley, CEO KCH UAE said at the launch.

Source: King’s College Hospital London’

Read more


 

 

 


Chest Diseases Hospital Extension

Construction  is under way of the Waleed and Abdul Rahman Intensive Care Centre , an extension to the Chest Diseases Hospital at the Al-Sabah Medical Area. The building will have a total built up area of 8,750 m2 and will House the following:

  • Patient and visitor amenities such as entrances, registration counters, waiting areas, food and beverage outlet, and administrative offices.
  • State-of-The-Art surgical theatres and an intensive care unit.
  • Critical care unit with patient wards
  • Staff community elements such as a 120-person auditorium, a banquet facility and a gym.

The design of this extension took into consideration historical and traditional architectural qualities while understanding the changes in knowledge and technology, and the impact this has on the lives and working habits of those using the building. We have, thus, developed a rational design language rooted in the classical architectural tradition by utilizing elements such as screens, shadows, simple forms, texture and scale.

Source: Gulf Consult

 

 

Expansion Plans HMC Qatar

 

The Hamad Medical Corporation (HMC) in Qatar is continuously expanding and developing it’s facilities and services in order to continue to meet the demands of Qatar’s rapidly growing population.

The Hamad Medical Corporation have embarked on the busiest expansion program in more than a decade as part of a government-wide program which will see seven new major hospitals open in Qatar over the next 18 months, creating more than 1100 new hospital beds between now and the end of December 2017.

There has already been significant progress against this program of work, such as the recent opening of clinics and services in the Communicable Disease Center, Qatar Rehabilitation Institute, Women’s Wellness and Research Center and Ambulatory Care Center.

Source: Hamad Medical Corporation

Photo Credit: Hamad Medical Corporation